ReleaseWire

Global Markets Direct's, 'Immunocore Limited - Product Pipeline Review - 2014', provides an overview of the Immunocore Limited's pharmaceutical research and development focus.

Global Markets Direct's, 'Ocular Hypertension - Pipeline Review, H2 2014', provides an overview of the Ocular Hypertension's therapeutic pipeline.

Global Markets Direct's, 'Enterocolitis - Pipeline Review, H2 2014', provides an overview of the Enterocolitis's therapeutic pipeline.

Global Markets Direct's, 'Vaxart, Inc. - Product Pipeline Review - 2014', provides an overview of the Vaxart, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Catabasis Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Catabasis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'AGY Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the AGY Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Corneal Graft Rejection - Pipeline Review, H2 2014', provides an overview of the Corneal Graft Rejection's therapeutic pipeline.

Global Markets Direct's, 'AlphaVax, Inc. - Product Pipeline Review - 2014', provides an overview of the AlphaVax, Inc.'s pharmaceutical research and development focus.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced positive interim data from the ongoing Phase I/II trial of Actimab-A in older patients with newly diagnosed Acute Myeloid Leukemia ("AML"). Most notably, median overall survival ("OS") of the seven secondary AML patients (with prior myelodysplastic syndrome, or MDS) in the study was 9.1 months, which is a prolongation of life compared to historical norms of typically 2 to 5 months.1 Older AML patients are already higher risk, with secondary AML patients considered to have the more severe and less treatable form of AML, and the shortest expected survival. The clinical abstract will be published and available online in Blood, the official Journal of the American Society of Hematology.

Global Markets Direct's, 'NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2014', provides an overview of the NAL Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Kissei Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Telangiectasis Global Clinical Trials Review, H2, 2014" provides data on the Telangiectasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Telangiectasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Telangiectasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014', provides an overview of the Waldenstrom Macroglobulinemia's therapeutic pipeline.

Global Markets Direct's, 'Morvus Technology Ltd - Product Pipeline Review - 2014', provides an overview of the Morvus Technology Ltd's pharmaceutical research and development focus.

Global Markets Direct's, 'Osteoarthritis - Pipeline Review, H2 2014', provides an overview of the Osteoarthritis's therapeutic pipeline.

Global Markets Direct's, 'Acute heart failure - Pipeline Review, H2 2014', provides an overview of the Acute heart failure's therapeutic pipeline.

Global Markets Direct's, 'Rhizen Pharmaceuticals SA - Product Pipeline Review - 2014', provides an overview of the Rhizen Pharmaceuticals SA's pharmaceutical research and development focus.

Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a provider for over the counter men's and women's health products, will release its third quarter 2014 financial results on Friday, November 14, 2014 when it expects to file its Form 10-Q for the 2014 third quarter.

Global Markets Direct's, 'Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Prostate Cancer's therapeutic pipeline.

Global Markets Direct's, 'Ebola Viral Infections - Pipeline Review, H2 2014', provides an overview of the Ebola Viral Infections's therapeutic pipeline.

Global Markets Direct's, 'Kaketsuken K.K. - Product Pipeline Review - 2014', provides an overview of the Kaketsuken K.K.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Acne Vulgaris - Pipeline Review, H2 2014', provides an overview of the Acne Vulgaris's therapeutic pipeline.

Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.

New data suggests the U.S. Drug Enforcement Agency’s crackdown on Hydrocodone prescriptions has positively affected painkiller-related deaths, with a 5 percent decrease. However, according to a study by the Centers for Disease Control and Prevention (CDC), heroin deaths have doubled in the past two years, leading Michael H. Lowenstein M.D., medical director for the Waismann Method treatment for opiate dependence, to believe prescription painkiller legislation may lead to a “win, lose” situation without prevention and treatment strategies in place.

Global Markets Direct's, 'Osteoporosis - Pipeline Review, H2 2014', provides an overview of the Osteoporosis's therapeutic pipeline.